WST · Company research
West Pharmaceutical Services, Inc. (WST): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
30records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| West Pharmaceutical Services (WST) Raises Quarterly Dividend by 18.2% - GuruFocus | West Pharmaceutical Services (WST) Raises Quarterly Dividend by 18.2% GuruFocus | View source ↗ | GuruFocus | Oct 20, 2026 | neutral | 0 | 0.6 |
| A company has raised its dividend for 34 straight years. Its next payment is $0.26 per share. - Stock Titan | A company has raised its dividend for 34 straight years. Its next payment is $0.26 per share. Stock Titan | View source ↗ | Stock Titan | Oct 19, 2026 | neutral | 0 | 0.6 |
| West Pharmaceutical Services Stock Price Forecast. Should You Buy WST? - StockInvest.us | West Pharmaceutical Services Stock Price Forecast. Should You Buy WST? StockInvest.us | View source ↗ | StockInvest.us | Oct 16, 2026 | neutral | 0 | 0.6 |
| West Pharmaceutical Services (WST) Earnings Date and Reports 2026 $WST - MarketBeat | West Pharmaceutical Services (WST) Earnings Date and Reports 2026 $WST MarketBeat | View source ↗ | MarketBeat | Oct 16, 2026 | neutral | 0 | 0.6 |
| West Pharmaceutical Services, I (WST) Stock forecasts - Yahoo Finance Australia | West Pharmaceutical Services, I (WST) Stock forecasts Yahoo Finance Australia | View source ↗ | Yahoo Finance Australia | Oct 15, 2026 | neutral | 0 | 0.6 |
| West Pharmaceutical Stock Gains 36.1% YTD: What's Behind the Rally? - TradingView | West Pharmaceutical Stock Gains 36.1% YTD: What's Behind the Rally? TradingView | View source ↗ | TradingView | Oct 15, 2026 | neutral | 0 | 0.6 |
| West Pharmaceutical Services, I (WST) Stock Forecasts - Yahoo Finance | West Pharmaceutical Services, I (WST) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| West Pharmaceutical Services, I (WST) Stock Forecasts - Yahoo Finance | West Pharmaceutical Services, I (WST) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 12, 2026 | neutral | 0 | 0.6 |
| Here's Why You Should Retain WAT Stock in Your Portfolio for Now | Waters Corporation (WAT) is positioned for growth driven by sustained analytical sciences demand, BD acquisition integration, and product innovation. The company projects 10.9% year-over-year earnings growth for 2026 with $50 million in revenue synergies and $75 million in cost savings expected. However, weakness in China diagnostics, BD integration execution risks, and dependence on customer capital spending present headwinds. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.75 | 1 |
| Third-quarter results are due before markets open Oct. 29; West Pharmaceutical's call follows at 8 a.m. - Stock Titan | Third-quarter results are due before markets open Oct. 29; West Pharmaceutical's call follows at 8 a.m. Stock Titan | View source ↗ | Stock Titan | Oct 8, 2026 | neutral | 0 | 0.6 |
| West Pharmaceutical Services (WST) Stock Could Be 17% Overvalued As Cash Flow Falls Short - Yahoo Finance | West Pharmaceutical Services (WST) Stock Could Be 17% Overvalued As Cash Flow Falls Short Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now | Fresenius Medical Care (FMS) is improving profitability through its FME25+ transformation program and showing promise with 5008X dialysis system adoption and value-based care expansion. However, the company faces significant headwinds including U.S. treatment volume weakness, TDAPA reimbursement reversals expected to create a €50 million headwind in 2026, China regulatory pressure, and inflation concerns. The company maintains a Zacks Rank #3 (Hold) rating with consensus expectations for 2.7% revenue growth but 5.4% earnings decline in 2026. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 0.75 | 1 |
| BDX Expands U.S. Manufacturing With $19B Healthcare Investment | Becton, Dickinson and Company (BD) announced a landmark partnership with the U.S. Government to invest $19 billion in domestic manufacturing expansion, including $3 billion toward manufacturing capacity. The company aims to increase domestically supplied essential medical consumables to 80% and manufacture all U.S.-used needles domestically with American-made steel. The agreement provides tariff protection on covered products, though financial impact remains unquantified pending finalization of tariff rates and implementation timing. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| BDX Expands U.S. Manufacturing With $19B Healthcare Investment | Becton, Dickinson and Company (BD) announced a landmark partnership with the U.S. Government to invest $19 billion in domestic manufacturing expansion, including $3 billion toward manufacturing capacity. The company aims to increase domestically supplied essential medical consumables to 80% and manufacture all U.S.-used needles domestically with American-made steel. The agreement provides tariff protection on covered products, though financial impact remains unquantified pending finalization of tariff rates and implementation timing. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| Reasons to Hold HealthEquity Stock in Your Portfolio for Now | HealthEquity reported solid fiscal Q2 2027 results with revenues up 7.6% and adjusted EPS rising 14.8%. HSA assets reached $37.9 billion with investments growing 20% year-over-year, while AI implementation reduced service costs and improved margins to 48%. The company raised fiscal 2027 adjusted EBITDA guidance to $628-$636 million. However, ongoing cybersecurity litigation and regulatory inquiries from a fiscal 2025 incident pose risks to future growth and profitability. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| Reasons to Hold HealthEquity Stock in Your Portfolio for Now | HealthEquity reported solid fiscal Q2 2027 results with revenues up 7.6% and adjusted EPS rising 14.8%. HSA assets reached $37.9 billion with investments growing 20% year-over-year, while AI implementation reduced service costs and improved margins to 48%. The company raised fiscal 2027 adjusted EBITDA guidance to $628-$636 million. However, ongoing cybersecurity litigation and regulatory inquiries from a fiscal 2025 incident pose risks to future growth and profitability. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| Veeva's DQS Scales Data Automation Across 1,000+ Clinical Studies | Veeva Systems' Data Quality System (DQS) platform has expanded its reach to support data cleaning across over 1,000 clinical studies involving more than 1 million subjects, generating 500,000+ automated queries. The platform's integration with AI, CTMS, and Study Builder Agent is expected to drive deeper customer engagement and recurring revenue growth in the life sciences software market. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| Veeva's DQS Scales Data Automation Across 1,000+ Clinical Studies | Veeva Systems' Data Quality System (DQS) platform has expanded its reach to support data cleaning across over 1,000 clinical studies involving more than 1 million subjects, generating 500,000+ automated queries. The platform's integration with AI, CTMS, and Study Builder Agent is expected to drive deeper customer engagement and recurring revenue growth in the life sciences software market. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| West Pharmaceutical Services (NYSE:WST) Stock Forecast & Analyst Predictions - Simply Wall Street | West Pharmaceutical Services (NYSE:WST) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 7, 2026 | neutral | 0 | 0.6 |
| Reasons to Retain Cardinal Health Stock in Your Portfolio for Now | Cardinal Health (CAH) expects Pharma profit growth of 8-11% in fiscal 2027 despite normalized demand, with other businesses projected to grow 15-18%. The company benefits from strong operational efficiency and specialty pharmaceutical growth, but faces headwinds from IRA pricing changes, moderating Specialty growth, and commodity cost pressures in its GMPD segment. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.75 | 1 |
| Reasons to Retain Cardinal Health Stock in Your Portfolio for Now | Cardinal Health (CAH) expects Pharma profit growth of 8-11% in fiscal 2027 despite normalized demand, with other businesses projected to grow 15-18%. The company benefits from strong operational efficiency and specialty pharmaceutical growth, but faces headwinds from IRA pricing changes, moderating Specialty growth, and commodity cost pressures in its GMPD segment. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.75 | 1 |
| Reasons to Retain Doximity Stock in Your Portfolio for Now | Doximity (DOCS) is experiencing strong clinical AI adoption with active workflow prescribers up 30% year-over-year and AI Scribe users growing 10-fold, validating its AI capabilities through independent studies. However, the company faces headwinds from modest overall revenue growth (7% YoY), declining gross margins (88% from 91%) due to elevated AI infrastructure costs, and a constrained pharma advertising market. While AI is opening new revenue opportunities, investors await evidence that AI monetization can materially accelerate consolidated growth. | View source ↗ | Zacks Investment Research | Oct 5, 2026 | bullish | 0.75 | 1 |
| Patient choice and drug-development risks are on the agenda for West's Milan talks - Stock Titan | Patient choice and drug-development risks are on the agenda for West's Milan talks Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| What Is Drawing Attention To West Pharmaceutical Services (WST)? - Yahoo Finance | What Is Drawing Attention To West Pharmaceutical Services (WST)? Yahoo Finance | View source ↗ | Yahoo Finance | Sep 20, 2026 | neutral | 0 | 0.6 |
| WST Stock Surges 38.1% Since March-End: What's Fueling the Rally? - Yahoo Finance | WST Stock Surges 38.1% Since March-End: What's Fueling the Rally? Yahoo Finance | View source ↗ | Yahoo Finance | Aug 14, 2026 | neutral | 0 | 0.6 |
| West Pharmaceutical Services (NYSE:WST) Beats Expectations in Strong Q2 CY2026, Stock Soars - StockStory | West Pharmaceutical Services (NYSE:WST) Beats Expectations in Strong Q2 CY2026, Stock Soars StockStory | View source ↗ | StockStory | Jul 23, 2026 | neutral | 0 | 0.6 |
| West Reports Second-Quarter 2026 Results - PR Newswire | West Reports Second-Quarter 2026 Results PR Newswire | View source ↗ | PR Newswire | Jul 23, 2026 | neutral | 0 | 0.6 |
| WST Stock Jumps on Q2 Earnings & Sales Beat, EPS View Up on HVP Growth - Yahoo Finance | WST Stock Jumps on Q2 Earnings & Sales Beat, EPS View Up on HVP Growth Yahoo Finance | View source ↗ | Yahoo Finance | Jul 23, 2026 | neutral | 0 | 0.6 |
| West (WST) Stock Looks Pricey With Little Room Above Fair Value - Yahoo Finance | West (WST) Stock Looks Pricey With Little Room Above Fair Value Yahoo Finance | View source ↗ | Yahoo Finance | Jul 21, 2026 | neutral | 0 | 0.6 |
| West Pharmaceutical Services (WST) Stock Looks Overvalued Despite Upcoming Q2 Earnings - Yahoo Finance | West Pharmaceutical Services (WST) Stock Looks Overvalued Despite Upcoming Q2 Earnings Yahoo Finance | View source ↗ | Yahoo Finance | Jul 4, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.